Oncology

Latest News

December 23rd 2024

Prior authorization, PBM reform, and payment for patient navigation were topics of the most popular articles in EBO in 2024.

ICYMI: Highlights From ASCO 2024

By Pearl Steinzor

December 21st 2024

chemotherapy | Image credit: Penn Medicine

The High Cost of Shortages of Low-Cost Chemotherapy

By Interview by Mary Caffrey

December 19th 2024

Leukemia diagnosis | Image credit: Vitalii Vodolazskyi - stock.adobe.com

Real-World Treatment Sequences and Cost Analysis of cBTKis in CLL

By Pearl Steinzor

December 17th 2024

FDA approved stamp in black with a red ribbon across it | Image credit: BHM - stock.adobe.com

Cosibelimab Approved for Metastatic or Locally Advanced Cutaneous Squamous Cell Carcinoma

By Kristi Rosa

December 16th 2024

Join this panel as they discuss treatment for metastatic NSCLC patients without driver mutations.

Watch the series now!

Watch Now

Join a panel of leaders as they discuss treatment for patients diagnosed with metastatic NSCLC without driver mutations

More News

December 16th 2017

Podcast: This Week in Managed Care—CAR T Treatments and Other Health News

Every week, The American Journal of Managed Care® recaps the top managed care news of the week, and you can now listen to it on our podcast, Managed Care Cast.

December 16th 2017

Diagnosing Non-Chemotherapy Drug-Induced Neutropenia

Laura Joszt, MA

In a session at the 59th American Society of Hematology Annual Meeting and Exposition in Atlanta, Georgia, Brian Curtis, PhD, of the BloodCenter of Wisconsin Blood Research Institute, highlighted drugs other than chemotherapy that may cause neutropenia in patients.

December 16th 2017

Average Profit Margin on Oncology Drugs for 340B Hospitals Nears 50%

Jaime Rosenberg

"The Oncology Drug Marketplace: Trends in Discounting and Site of Care," commissioned by the Community Onoclogy Alliance and conducted by Berkley Research Group, found that 340B hospitals have a clear financial incentive to expand oncology services; 340B hospitals receive over one-third of all Part B oncology drug reimbursement; a disproportionate share of the shift in site of care is attributable to 340B hospitals; and between 2010 and 2015, statutory discounts and rebates paid by manufacturers have almost tripled and put upward pricing pressure on drugs.

December 15th 2017

Majority of Women With Breast Cancer Surgery Did Not Feel Fully Informed of Treatment Options

Jaime Rosenberg

The majority of women who underwent a lumpectomy or a mastectomy reported not feeling fully informed of their treatment options, but the use of Web-based decision aids can help patients become informed, according to results of 2 new studies published in the Journal of the American College of Surgeons.

December 15th 2017

5 Key Takeaways From ASH 2017

Surabhi Dangi-Garimella, PhD

Discussions at the 59th Annual Meeting and Exposition of the American Society of Hematology (ASH) included progress reports on genetically modified immunotherapy treatments, a new treatment paradigm for advanced Hodgkin lymphoma, possibility of treatment-free remission in chronic myelogenous leukemia, and challenges with hospice utilization for patients with leukemia.

December 15th 2017

This Week in Managed Care: December 15, 2017

This week, the top managed care news included coverage from the 59th American Society of Hematology Annual Meeting and Exposition; recommendations on the use of diabetes drugs with cardiovascular indications; and a new study found that despite changes in insurance plans to give consumers more clout, unnecessary medical spending remains a problem.

December 15th 2017

Navigating the Quality Landscape in Oncology: Pitfalls and Lessons Learned

Surabhi Dangi-Garimella, PhD

The conclusion drawn by panelists participating at the National Comprehensive Cancer Network’s Oncology Policy Summit on Redefining Quality Measurement in Oncology was that ensuring access to appropriate data and using that information to improve healthcare outcomes remains an ongoing challenge.

December 15th 2017

Lending the Patient Voice to Oncology Quality Measurement

Surabhi Dangi-Garimella, PhD

Speaking at the National Comprehensive Cancer Network Oncology Policy Summit on Redefining Quality Measurement in Oncology, Ronald Walters, MD, MBA, MHA, MS, associate vice president of medical operations and informatics at The University of Texas MD Anderson Cancer Center, emphasized the need to focus on the patient’s preferences and values in cancer care delivery.

December 14th 2017

Report Highlights Increase in Premature Deaths in the United States

Laura Joszt, MA

An analysis of behaviors, community environment, policy, clinical care, and outcomes data has found a disturbing trend in mortality in the United States, with premature deaths, drug deaths, and cardiovascular deaths all increasing.

December 14th 2017

Q&A With Dr Thomas LeBlanc: The Value of ePROs in Oncology

Surabhi Dangi-Garimella, PhD

The FDA has recognized the need to include the patient's voice in the drug development process. The question is: what is the best way to do this?

December 14th 2017

FDA Announces Public Education Campaign to Encourage Smoking Cessation

Jaime Rosenberg

The FDA has announced its launch of the “Every Try Counts” campaign, which will encourage smokers to quit by advertising messages of support underscoring the health benefits of quitting. The campaign will also focus on celebrating each quit attempt as a step towards success.

December 13th 2017

Halt and Catch Fire: Can the Digital Revolution Empower the Move Toward Value-Based Cancer Care?

Joseph Alvarnas, MD

There is no shortage of academic, industry, and government sources that identify value as equaling cost/outcomes; there is far less uniformity of opinion when it comes to defining what that means for a particular patient affected by cancer.

December 13th 2017

How Technology, Social Media Are Changing the Way Clinical Trials Connect With Patients

Mary Caffrey

New companies are finding patients for clinical trials in remote locations and trimming months off the enrollment process.

December 13th 2017

Dr Stephen Schuster Outlines CAR T Results Seen in Leukemia, Lymphoma, and Myeloma

Stephen Schuster, MD, of the Perelman School of Medicine, provides a summary of results seen with CAR T treatments in leukemia, lymphoma, and myeloma.

December 13th 2017

New Treatment Paradigm Supersedes ABVD in Advanced Hodgkin Lymphoma: The ECHELON-1 Study

Surabhi Dangi-Garimella, PhD

Including the modified brentuximab antibody in the treatment regimen improved modified progression-free survival by 5%, although the rates of neutropenia and infections were higher in patients administered the brentuximab-containing regimen.

December 12th 2017

Dr Julie Wolfson Highlights Different Outcomes in AYAs With ALL Compared With Children

Adolescents and young adults with acute lymphoblastic leukemia (ALL) tend to have worse outcomes than children with ALL, and new research published at the 59th American Society of Hematology Annual Meeting delved into the reasons why, explained Julie A. Wolfson, MD, of the University of Alabama at Birmingham School of Medicine.

December 12th 2017

Dr Joshua Richter Discusses Patient Financial Burden of New Treatments and Cures

Right now is a critical time for the healthcare industry to evaluate how patients are financially burdened by novel treatments that can provide tremendous outcomes, said Joshua R. Richter, MD, of the John Theurer Cancer Center.

December 12th 2017

EHR Documentation and the Patient–Physician Visit

Sheree Starrett, MD, MS

The need for physicicans to gather information for electronic health records has changed the nature of the patient visit.

December 12th 2017

CAR T Progress: Global Submissions for Kymriah, 42% Ongoing Response With Yescarta in ZUMA-1 Patients

Surabhi Dangi-Garimella, PhD

A much-anticipated session on the second day of the 59th Annual Meeting and Exposition of the American Society of Hematology provided long-term updates on trials evaluating 2 chimeric antigen receptor-T (CAR T) treatments: tisagenlecleucel or CTL019 (Kymriah) for the treatment of adult relapsed/refractory diffuse large B-cell lymphoma (DLBCL) and axicabtagene ciloleucel (Yescarta) evaluated in patients with refractory aggressive non-Hodgkin lymphoma.

December 12th 2017

Racial Disparities Prevalent in Survival of Patients With Ovarian, Colon, and Breast Cancer

Jaime Rosenberg

Findings from 3 analyses published in CANCER highlight racial disparities in the survival of patients with ovarian, colon, and breast cancer from 2001-2003 and 2004-2009.

December 11th 2017

Clonal Expansion and Aging Fuel the Development of Neoplasms, Say Experts at ASH

Surabhi Dangi-Garimella, PhD

Clonal hematopoiesis and selection pressures associated with aging can together lead to the development of neoplasms. Two hematologists presented US and European updates on the potential to develop a predictive model, and an appropriate intervention, in these individuals.

December 11th 2017

CTL019 More Cost Effective in Pediatric Patients With Acute Lymphoblastic Lymphoma

Jaime Rosenberg

Two abstracts at the 59th Annual Meeting of the American Society of Hematology in Atlanta, Georgia found that CTL019 shows promising potential in providing significant benefit and cost effectiveness for pediatric and young adult patients with B-cell acute lymphoblastic leukemia in both the United States and the United Kingdom.

December 10th 2017

Dr Derek Raghavan Outlines Challenges to Implementing Evidence-Based Guidelines

Physician belief in the art of medicine is running up against the challenge of costs being shifted to patients and health systems and the desire of payers to have less variation in care, said Derek Raghavan, MD, PhD, FACP, FRACP, president, Carolinas HealthCare System's Levine Cancer Institute.

December 10th 2017

Dr Kerry Rogers: Ibrutinib's Impact on Vaccine Response

Ibrutinib has the potential to improve vaccine response for patients with chronic lymphocytic leukemia, and an ongoing trial will help provide a better understanding, explained Kerry Rogers, MD, assistant professor, internal medicine, Division of Hematology, The Ohio State University Comprehensive Cancer Center.

December 10th 2017

Single-Agent Ibrutinib Promising in MCL and CLL, Improves Patient Well-Being

Surabhi Dangi-Garimella, PhD

Three studies presented at the ongoing 59th Annual Meeting and Exposition of the American Society of Hematology in Atlanta, Georgia, shared progress on the oral Bruton’s tyrosine kinase inhibitor, ibrutinib, in the treatment of relapsed/refractory mantle cell lymphoma (MCL) and as a single agent in chronic lymphocytic leukemia (CLL).

December 10th 2017

Treatment-Free Remission and Preventing Cardiotoxicity: The Future of CML Care

Surabhi Dangi-Garimella, PhD

During a session on the first day of the 59th Annual Meeting and Exposition of the American Society of Hematology in Atlanta, Georgia, physicians shared current knowledge on cardiovascular toxicities of tyrosine kinase inhibitors (TKIs) as well as the potential for treatment-free remission with these agents.

December 9th 2017

UC San Diego Researchers Receive $600,000 Grant to Test PI3Ky Inhibitor

Kelly Davio

A University of California San Diego School of Medicine and Moores Cancer Center research team studying new drugs that could break resistance to cancer immunotherapy has received a 3-year, $600,000 translational grant from the V Foundation for Cancer Research.

December 8th 2017

This Week in Managed Care: December 8, 2017

This week, the top managed care stories included CVS' proposal to purchase Aetna, which could reshape healthcare; a new study that looks at who is dying in hospitals from opioid use; and CMS reported that healthcare spending grew more slowly in 2016.

December 8th 2017

Ribociclib Plus Oral Endocrine Partner Shows Efficacy in Women With HR+/HER2- Breast Cancer

Jaime Rosenberg

Novartis announced that Phase III MONALEESA-7 trial results showed that the combination of ribociclib with an endocrine therapy (tamoxifen or an aromatase inhibitor) and goserelin yielded significant progression-free survival when compared with endocrine therapy and goserelin alone.

December 6th 2017

How Physicians Handle Differing Guidelines on Breast Cancer Screening Recommendations

Laura Joszt, MA

WIth different societies and organizations releasing contrary guidelines around breast cancer screening, experience with past patients or friends and family members could influence physicians' decisions around when to start screening mammography.

...

56 57 58 59 60 61 62 63 64

...

181 >

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

Do Not Sell My Information

Terms & Conditions